Teva Pharmaceutical Industries Limited Drug Halved Risk of Full-Blown Multiple Sclerosis in Vita-Salute University Study

Published: Oct 07, 2009

Bookmark and Share

Oct. 7 (Bloomberg) -- Teva Pharmaceutical Industries Ltd.’s Copaxone drug can cut the likelihood of patients progressing to full-blown multiple sclerosis almost in half, researchers said.

Back to news